Exploring New Combination Strategy of Lipid-Lowering Therapies for Primary Prevention of Cardiovascular Disease

초록

Cardiovascular disease (CVD) is the leading cause of death globally. Metabolic, behavioral, environmental, and occupational risk factors significantly influence the incidence and progression of CVD. Among the top cardiovascular risk factors are high blood pressure, dietary risks, and elevated levels of low-density lipoprotein cholesterol (LDL-C).(1) )Therefore, lowering LDL-C levels is one of the most effective strategies for preventing CVD. Statin therapy is the cornerstone of this approach, with numerous randomized controlled trials (RCTs) demonstrating its effectiveness in the primary prevention of CVD ( Table 1 ).(2-5)) According to a recent meta-analysis (23 RCTs and 3 observational studies; n=513,291), statin therapy for the primary prevention of CVD was associated with a reduced risk of all-cause mortality (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.87-0.98) and CVD events (HR, 0.72; 95% CI, 0.64-0.81).(6) )Benefits of statin therapy appeared to be present across diverse demographic and clinical populations. Consequently, the US Preventive Services Task Force recommends statin use for primary prevention in individuals aged 40 to 75 years with no history of CVD, who have one or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD event risk of 10% or greater.

키워드